- About Us
- Contact Us
Construction is complete for JSBio's cell culture medium production facility ("CCM2") located on the coast of the East China Sea. Now that the building is complete, installation of equipment and consumables will take place before our staff joins to prepare the facility for operation. Production is officially scheduled to begin later this year.
CCM2 is a subsidiary of Jianshun Biosciences and Thousand Oaks Biologics, serving as the company's second production facility for culture medium following Lanzhou. With a total investment of several hundred million yuan on a 28-acre plot of land, this new construction will be home to R&D laboratories in addition to our largest production facility. The new site houses the most advanced cell culture medium production technology as we aim to ensure the highest degree of product quality achievable. Once complete and in service, CCM2 will be capable of producing more than a thousand tons of dry powder medium for our customers each year. Production at CCM2 is managed byan organized system enabling us to maintain communication with our suppliers of raw materials, monitor raw material stability, and ensure that our staff is properly trained to handle materials at each stage of production. Our system is designed to promote product and service quality in a time and cost-efficient manner by utilizing the most advanced scientific technology and the best quality large-scale equipment available in the world. At JSBio, we are determined to establish affordable and accessible solutions for the biopharmaceutical industry in China and around the world.
Since its establishment ten years ago, JSBio has been committed to the exploration, development, and application of serum-free cell culture media. Our most important business philosophy is "Quality First, Customer Focused" and we continue to redefine the best ways to achieve this aim. JSBio has successfully completed China's Class I Medical Device certification and ISO Quality Management System certification. Our production facilities will continue to manufacture human and veterinary vaccines and biologics using the most advanced technology and highest quality raw materials available in the industry. We appreciate our past and current customers for consistently recognizing our product and service management system as being efficient beyond their expectations. The opening of our CCM2 facility will provide numerous benefits especially regarding technological enhancements and production capacity.